<DOC>
	<DOCNO>NCT00005846</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : This phase I/II trial study side effect tipifarnib see well work treat patent myeloproliferative disorder .</brief_summary>
	<brief_title>Tipifarnib Treating Patients With Myeloproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect tipifarnib adult patient myeloproliferative disorder . - Determine hematological response , include change WBC count erythroid response , patient population treat drug . - Determine cytogenetic response bone marrow patient treat drug . OUTLINE : This multicenter study . Patients stratify accord prior substantive treatment ( yes v ) . Patients receive oral tipifarnib twice daily day 1-21 . Treatment repeat every 4 week maximum 4 course absence unacceptable toxicity disease progression . Patients continue hematologic response completion fourth course may receive additional course discretion investigator . PROJECTED ACCRUAL : A total 25 patient ( 12-13 per stratum ) accrue study within 25 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia ( CML ) Philadelphia chromosome ( Ph ) positive OR BCRABL positive polymerase chain reaction Must meet 1 follow 2 condition : Chronic phase Persistent progressive disease maximum tolerate interferon imatinib mesylate , evidence increase WBC count , peripheral blood myeloid immaturity , progressive anemia , and/or persistence relapse abnormal cytogenetics and/or molecular finding Interferon imatinib mesylate intolerant Accelerated phase Persistent progressive disease imatinib mesylate Patients receive interferon imatinib mesylate due allergy refusal eligible OR Diagnosis chronic myelomonocytic leukemia Proliferative type ( WBC least 12,000/mm3 ) Less 5 % blast peripheral blood 20 % blast bone marrow OR Diagnosis undifferentiated myeloproliferative disorder OR Diagnosis atypical CML ( Ph negative ) No blast crisis phase CML , atypical CML , undifferentiated myeloproliferative disorder No 20 % blast peripheral blood bone marrow Diagnosed 3 month study entry PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 02 Life expectancy : More 4 month Hematopoietic : See Disease Characteristics No requirement platelet transfusion No thrombocytopeniarelated bleed Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2 time ULN Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Capable swallow capsule No concurrent severe disease would preclude study compliance No septicemia severe infection No iron deficiency If marrow aspirate available , transferrin saturation least 20 % ferritin great 50 ng/mL No contributing cause anemia ( e.g. , autoimmune hereditary hemolytic disorder , gastrointestinal blood loss , B12 folate deficiency , hypothyroidism ) PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior interferon At least 4 week since prior hematopoietic growth factor No prior allogeneic bone marrow transplantation Chemotherapy : At least 4 week since prior cytotoxic chemotherapy ( 6 week mitomycin nitrosoureas ) except hydroxyurea may use manage elevate cell count begin second course study therapy Endocrine therapy : No concurrent androgens No concurrent corticosteroid ( e.g. , great 10 mg/day prednisone equivalent steroid dosage ) except premedication transfusion Radiotherapy : Not specify Surgery : Not specify Other : No concurrent standard investigational cytotoxic agent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>